There is a newly created Tasigna multi-district litigation (MDL) for those Tasigna drug injury lawsuits filed in the federal court system. We get some of the reasoning for this consolidation of Tasigna side effects cases from the August 10, 2021, JPML Transfer Order issued for IN RE: TASIGNA (NILOTINIB) PRODUCTS LIABILITY LITIGATION, MDL No. … [Read more...]
Imbruvica Increases Risks Of Myocardial Infarctions, Strokes, And Cardiovascular Deaths
Serious heart-related side effects such as myocardial infarctions, strokes, and cardiovascular deaths associated with Imbruvica (ibrutinib), according to this medical journal article, “Hypertension and Incident Cardiovascular Events Following Ibrutinib Initiation”, published in early October 2019. From the Abstract for this Blood medical journal … [Read more...]
Uloric Warning: Avoid Uloric If Prior Myocardial Infarction, Stroke, Or Unstable Angina
The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) issued a Uloric warning in July 2019 stating that patients with prior myocardial infarction, stroke, or unstable angina should avoid Uloric as there is a higher risk of death. From this July 2019 MHRA Drug Safety Update, “Febuxostat (Adenuric): increased risk of … [Read more...]
Zelnorm: FDA Approval In 2019 (After 2007 Recall) Despite Continuing Cardiovascular Safety Concerns
In April 2019 we learned that the FDA is allowing Zelnorm back on the market 12 years after there was an FDA-mandated Zelnorm recall. From this April 3, 2019 Healio article, “FDA approves reintroduction of Zelnorm for IBS-C in certain women”, we get this significant point: Sloan Pharmaceuticals [(the responsible drug company)], a subsidiary of … [Read more...]
February 2019: Uloric “Black-Box Warning” For Heart-Related Deaths, Cardiovascular Side Effects
The FDA has required its strongest safety warning, i.e., Bolded Warning or Black-Box Warning, be included on a new Uloric drug label to inform about the increased risk of heart-related death and death from all causes with Uloric. From this February 2019 FDA Drug Safety Communication, "FDA adds Boxed Warning for increased risk of death with gout … [Read more...]
Pradaxa And Xarelto May Double The Risk Of Heart Attacks Some Patients
In March 2017 the British Journal of Clinical Pharmacology published this article, “Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants”, which reports on the first retrospective cohort study to compare the risk of acute myocardial infarction (AMI), or heart … [Read more...]
Farxiga / Jardiance / Invokana: Label Change Adds Ketoacidosis Warning
In August 2016 the FDA sent letters to Janssen Pharmaceuticals and AstraZeneca Pharmaceuticals for label changes about fatal cases of ketoacidosis cases involving Invokana (canagliflozin), Invokamet (canagliflozin and metformin), Farxiga (dapagliflozin), and Xigduo XR (dapagliflozin and metformin extended-release). As for the other diabetes … [Read more...]